Table 4.

Characteristics and tests for each analysis

	ESS	MWT	Cataplexya	NSb	OSSc	B/Rd	EDSe	B/Rf
No. of studies	12	12	8	14	13	13	13	12
N pairwise computations	22	20	16	24	23	23	23	22
I 2	0.51	0.73	0.32	0.57	0.81	0.58	0.53	0.6
Tests
Overall Q	0.01	<.001	0.17	<.001	<.001	<.001	0.01	<.001
Within Qh	0.16	<.001	0.51	0.01	<.001	<.001	0.01	<.001
Between Qi	0.04	0.6	0.09	0.09	0.04	0.19	0.24	0.32
P scores
Modafinil	0.73	0.49	0.27	0.57	0.45	0.50	0.70	0.72
P20	0.19	0.38	0.31	0.29	0.55	0.30	0.32	0.33
P40	0.80	0.83	0.88	0.85	0.56	0.87	0.89	0.90
Placebo	0.12	0.15	0.18	0.09	0.86	0.12	0.15	0.19
SX6	0.36	0.48	0.57	0.48	0.49	0.51	0.25	0.29
SX9	0.78	0.67	0.79	0.73	0.07	0.61	0.68	0.58

Number of studies, number of pairwise computations, heterogeneity index I², and tests (Overall Cochran Q statistics measuring distinctions between net estimates and observed differences, split into within-design Q_h, measuring heterogeneity between studies, and between-designs Q_i, incorporating the concept of design inconsistency) for the following analyses: ESS, MWT, cataplexy, narcolepsy Z score, safety, and benefit/risk ratio.

MDF = modafinil, CTP = cataplexy rate.

^aWeekly reduction of cataplexy rate (CTP).

^bNarcolepsy score.

^cOverall safety score.

^dBenefit/risk ratio, calculated as the residual of the linear fit of the NS by the OSS.

^eEDS Z score.

^fBenefit/risk ratio based on efficacy limited to EDS, and calculated as the residual of the linear fit of EDS Z score by OSS.